TG Therapeutics Inc

NASDAQ:TGTX  
33.31
-0.64 (-1.88%)
Products

TG Therapeutics Submits Biologics License Application To U.S. FDA For Ublituximab As Treatment For Patients With Relapsing Forms Of Multiple Sclerosis

Published: 09/30/2021 11:46 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab As a Treatment for Patients With Relapsing Forms of Multiple Sclerosis.